| Literature DB >> 28659908 |
Shih-Chun Yang1, Chih-Hua Tseng2,3,4,5, Pei-Wen Wang6, Po-Liang Lu7,8, Yi-Han Weng1, Feng-Lin Yen5,9, Jia-You Fang1,10,11.
Abstract
Pterostilbene is a methoxylated derivative of resveratrol originated from natural sources. We investigated the antibacterial activity of pterostilbene against drug-resistant Staphylococcus aureus and the feasibility of using it to treat cutaneous bacteria. The antimicrobial effect was evaluated using an in vitro culture model and an in vivo mouse model of cutaneous infection. The minimum inhibitory concentration (MIC) assay demonstrated a superior biocidal activity of pterostilbene compared to resveratrol (8~16-fold) against methicillin-resistant S. aureus (MRSA) and clinically isolated vancomycin-intermediate S. aureus (VISA). Pterostilbene was found to reduce MRSA biofilm thickness from 18 to 10 μm as detected by confocal microscopy. Pterostilbene showed minimal toxicity to THP-1 cells and was readily engulfed by the macrophages, facilitating the eradication of intracellular MRSA. Pterostilbene exhibited increased skin absorption over resveratrol by 6-fold. Topical pterostilbene application improved the abscess formation produced by MRSA by reducing the bacterial burden and ameliorating the skin architecture. The potent anti-MRSA capability of pterostilbene was related to bacterial membrane leakage, chaperone protein downregulation, and ribosomal protein upregulation. This mechanism of action was different from that of resveratrol according to proteomic analysis and molecular docking. Pterostilbene has the potential to serve as a novel class of topically applied agents for treating MRSA infection in the skin while demonstrating less toxicity to mammalian cells.Entities:
Keywords: MRSA; biofilm; proteomics; pterostilbene; resveratrol; skin infection
Year: 2017 PMID: 28659908 PMCID: PMC5468402 DOI: 10.3389/fmicb.2017.01103
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1The chemical structures, molecular weights (M.W.), and partition coefficients (log P) of resveratrol and pterostilbene. The log P was calculated by Discovery Studio® (Accelrys, San Diego, CA, USA).
The MIC and MBC of MRSA, VISA, and P. aeruginosa after treatment of resveratrol and pterostilbene.
| MRSA (ATCC 33591) | 1.25 | 0.16~0.63 | 5.00~10.00 | 0.16~0.63 |
| MRSA (KM-1) | 1.25 | 0.078 | 5.00~10.00 | 0.078~0.156 |
| MRSA (KM-2) | 1.25 | 0.078 | 5.00~10.00 | 0.078 |
| VISA (KV-1) | 1.25 | 0.078 | 5.00~10.00 | 0.078~0.156 |
| VISA (KV-5) | 1.25 | 0.078 | 5.00~10.00 | 0.078~0.156 |
| 5.00 | 5.00 | 10.00 | 5.00~10.00 | |
KM-1, KM-2, KV-1, and KV-2 are the clinical isolates of bacteria.
Each value represents the mean ± S.D. (n = 3).
Figure 2Antibacterial activity of resveratrol and pterostilbene: (A) the live MRSA strain viewed under confocal microscopy, (B) zone of inhibition measured from disk diffusion assay, and (C) total protein amount in MRSA. Each value represents the mean and SD (n = 4).
Figure 3Anti-MRSA activity of pterostilbene: (A) Morphological changes of MRSA viewed under TEM, (B) the three-dimensional images of biofilm, (C) the corresponding biofilm thickness, and (D) intracellular MRSA killing in macrophages (THP-1). Each value represents the mean and S.D. (n = 4).
Nude mouse skin permeation parameters of resveratrol and pterostilbene after in vitro percutaneous absorption from 20% PG/pH 7.4 buffer suspension at a determined concentration (15 mM) and at a saturated concentration.
| Resveratrol | 1.71 ± 0.62 | 5.98 ± 1.20 | 11.78 | 0.24 ± 0.05 | 2.70 ± 2.64 | 1.65 |
| Pterostilbene | 10.40 ± 1.03 | 41.38 ± 1.14 | 107.33 | 1.29 ± 0.21 | 13.00 ± 1.11 | 13.31 |
TI, therapeutic index = skin deposition or CSA x antibacterial inhibition zone.
CSA, calibrated skin accumulation = cumulative amount in the skin/saturated solubility.
K.
The data represent the mean ± S.D. (n = 4).
Figure 4In vivo topical application of pterostilbene against MRSA: (A) The skin surface of mice after treatment of MRSA at day 1, 3, and 7; (B) Transepidermal water loss (TEWL) of mice skin treated with MRSA; (C) Yellow/blue color (b*) of mice skin treated with MRSA; (D) Survival of MRSA in mice skin treated with MRSA. Seven days after infection, skin lesions were cut, homogenized, and bacterial count was determined by CFU assay, and (E) Histological observation of mice skin biopsy after treatment of MRSA. On day 7, biopsy specimens were taken immediately after the termination of the experiment and stained with hematoxylin and eosin (H&E). Scale bar = 50 μm. Each value represents the mean and S.D. (n = 6).
Figure 5In vitro cytotoxicity of resveratrol and pterostilbene to: (A) HaCaT keratinocyte cell viability measured by MTT assay; (B) HaCaT keratinocyte cell viability measured by ATP assay; and (C) human neutrophils determined by LDH release. Each value represents the mean ± S.D. (n = 4). *p < 0.05.
Figure 6Skin tolerance examination of mouse skin a 7-day treatment of topically applied pterostilbene: (A) Macroscopic appearance and (B) skin specimen stained with hematoxylin and eosin (H&E).
Figure 7The effect of resveratrol and pterostilbene on MRSA proteins: (A) The protein change of MRSA after treatment with resveratrol and pterostilbene analyzed by SDS-PAGE and MALDI-TOF/TOF mass and (B) Superimposition of the computed poses for resveratrol/pterostilbene and proteins. The molecular docking was calculated by Discovery Studio® (Accelrys, San Diego, CA, USA).
Differentially expressed proteins follow resveratrol and pterostilbene treatments.
| 1 | Chaperone protein ClpB (CLPB) | 87,165 | 27 | 45% (191) | 3.85 ± 0.04 | −1.26 ± 0.02 | 0.038 | Part of a stress-induced multi-chaperone system, it is involved in the recovery of the cell from heat-induced damage, in cooperation with DnaK, DnaJ, and GrpE. | |
| 2 | Chaperone protein DnaK (DNAK) | 66,321 | 18 | 43% (123) | 5.41 ± 0.07 | −1.50 ± 0.04 | 0.041 | Acts as a chaperone. | |
| 3 | Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) | 36,382 | 12 | 48% (117) | 1.50 ± 0.02 | −3.82 ± 0.06 | 0.028 | Catalyzes the oxidative phosphorylation of glyceraldehyde 3-phosphate (G3P) to 1,3-bisphosphoglycerate (BPG) using the cofactor NAD. | |
| 4 | 50S ribosomal protein L6 (RL6) | 19,802 | 10 | 62% (96) | 1.62 ± 0.11 | 2.27 ± 0.01 | 0.036 | This protein binds to the 23S rRNA, and is important in its secondary structure. It is located near the subunit interface in the base of the L7/L12 stalk, and near the tRNA binding site of the peptidyltransferase center. | |
| 5 | Elongation factor G (EFG) | 76,877 | 29 | 45% (212) | −3.19 ± 0.07 | −1.47 ± 0.13 | 0.025 | Catalyzes the GTP-dependent ribosomal translocation step during translation elongation. | |
| 6 | Arginine deiminase (ARCA) | 47,069 | 20 | 46% (145) | −2.57 ± 0.03 | −1.50 ± 0.05 | 0.036 | L-arginine + H2O = L-citrulline + NH3. | |
| 6 | Glucose-6-phosphate isomerase (G6PI) | 49,849 | 14 | 48% (93) | −2.26 ± 0.05 | −1.42 ± 0.01 | 0.048 | D-glucose 6-phosphate = D-fructose 6-phosphate. | |
| 7 | Citrate synthase 2 (CISY2) | 40,614 | 10 | 31% (92) | −3.37 ± 0.02 | −2.17 ± 0.02 | 0.013 | Might regulate the synthesis and function of enzymes involved in later enzymatic steps of Krebs cycle. Loss in activity results in sporulation defect. | |
| 8 | Phosphoenolpyruvate carboxykinase [ATP] (PCKA) | 58,803 | 19 | 36% (102) | 1.52 ± 0.04 | 2.83 ± 0.01 | 0.032 | Involved in the gluconeogenesis. Catalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP) through direct phosphoryl transfer between the nucleoside triphosphate and OAA. | |
| 9 | 30S ribosomal protein S4 (RS4) | 23,027 | 21 | 61% (159) | −1.40 ± 0.05 | 2.69 ± 0.01 | 0.018 | One of the primary rRNA binding proteins, it binds directly to 16S rRNA where it nucleates assembly of the body of the 30S subunit. | |
| 10 | Alkaline shock protein 23 (ASP) | 19,210 | 11 | 68% (124) | 1.59 ± 0.01 | 2.93 ± 0.01 | 0.021 | May play a key role in alkaline pH tolerance. | |
| 11 | 30S ribosomal protein S13 (RS13) | 10,343 | 10 | 89% (92) | 1.59 ± 0.01 | 2.03 ± 0.05 | 0.010 | May function as a redox-sensitive chaperone and as a sensor for oxidative stress. | |
Ratios to control indicated the fold changes in protein volume between resveratrol-, pterostilbene-treated samples vs. control samples, respectively. The higher ratios (>1.0) mean the proteins whose expression levels were increased upon treatments of compounds, while lower ratios (<−1.0) indicate the proteins were downregulated under the exposure to compounds.
p-values were generated by analyzing the gel images using Prodigy SameSpots™ software. Differences were considered significant at p < 0.05 after the comparison of the ratios to control between resveratrol and pterostilbene groups.